Semaglutide 2.4 mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery
Authors' conclusion
This study is the first, to the authors' knowledge, to compare the effectiveness of semaglutide treatment in patients with versus those without a history of BS, providing valuable evidence of its efficacy. By focusing on individuals with severe obesity (BMI > 40 kg/m2 and associated comorbidities), it fills a gap in the current literature and highlights the potential of semaglutide 2.4 mg as a treatment option for this specific population.
Study context
- Population
- Patients with severe obesity (BMI ≥ 40 kg/m²); Bariatric surgery (BS)+ had failed to achieve satisfactory weight loss or experienced weight regain after BS
- Participants
- 129 patients
- Exposure
- Semaglutide 2.4 mg in patients with vs without a history of BS
- BS+n = 39
- BS-n = 90reference
- Outcome
- Percentage of weight loss
- Follow-up
- 24 weeks
Methodological detailsSemaglutide for 24 weeks, from 0.25 mg/wk titrated to 2.4 mg/wk
- Semaglutide for 24 weeks, from 0.25 mg/wk titrated to 2.4 mg/wk
Main finding
As reported in the abstract
Weight loss
BS+
9.1%
Observational data: associations, not effects.
Original publication
Semaglutide 2.4 mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery. Obesity (Silver Spring). Published 5 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →